BioSpace News Archive

1910 Genetics Appoints Desney Tan from Microsoft to Board of Directors.

Innovation Pharmaceuticals today updated shareholders on recent progress by BT BeaMedical Technologies Ltd. to advance its new image guided surgical laser platform for treating previously inoperable cases of epilepsy and for enabling new treatment options for cancer cases in multiple specialties.

ImmPACT Bio USA , Inc. today announced the appointment of Jonathan Benjamin, M.D., Ph.D. as its chief medical officer.

QurAlis Corporation, a biotech company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, today announced that Kasper Roet, Ph.D., founder and chief executive officer, will present at the 22nd Annual Biotech in Europe Forum.

Elidah Inc., a growing medical solutions company that focuses on delivering FDA-cleared, clinically-proven treatment devices for difficult-to-treat female health urinary conditions announced that it has signed a national agreement with VGM & Associates.

Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the appointment of Athena Countouriotis, M.D., as the chairperson of the board of directors.

TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, has expanded its GMP-grade product offering to include N1-Methyl-Pseudouridine-5’-Triphosphate, a modified nucleoside-triphosphate essential for mRNA manufacturing.

Axial Therapeutics Inc. today announced that A. Stewart Campbell, Ph.D., will participate in a panel entitled “The Next Wave of Targeted Therapies” at the Longwood Healthcare Leaders Fall webconference on Wednesday, September 21, 2022.

Cidara Therapeutics, Inc. today announced the initiation of its Phase 2a trial to evaluate the pre-exposure prophylactic activity of CD388 against influenza virus. CD388 is a highly potent, long-acting antiviral designed to deliver universal prevention of seasonal and pandemic influenza.

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the comparative bioavailability, pharmacokinetics, and safety of its oral betamethasone spray, GTX-102, compared to an intramuscular injection of betamethasone and to an oral solution of betamethasone, in 48 healthy subjects.